The year 2020 will be remembered for its tragic events, but in its wake, companies like Poolbeg Pharma are leading efforts to prepare for future pandemics. Richard Staines from Optimum Strategic Communications interviewed Jeremy Skillington, the CEO of Poolbeg Pharma, to explore how the company is harnessing artificial intelligence (AI) to accelerate the discovery of new drugs for influenza.
Poolbeg Pharma is developing a drug designed to mitigate some of the most severe effects of influenza. This drug aims to neutralise the body’s excessive immune response, known as a “cytokine storm,” which is responsible for many of the severe symptoms following a flu infection.
In this expert discussion, Tushar Pandey, CEO and Co-founder of SimBioSys, also shares insights into the role of AI in drug development. Pandey and Skillington provide valuable perspectives on the potential of AI to revolutionise the pharmaceutical industry, particularly in expediting the discovery and development of crucial medications.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
